Evidence map›Paper›PMID 36298733›Full record

ArticleViruses2022

Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2.

Shang Yu Gong, Shilei Ding, Mehdi Benlarbi, Yaozong Chen, Dani Vézina, Lorie Marchitto, Guillaume Beaudoin-Bussières, Guillaume Goyette, Catherine Bourassa, Yuxia Bo and 7 more

Abstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. SARS-CoV-2 and Environmental Changes: The Perfect Storm.Current issues in molecular biology · 2024
    Review
  5. Will COVID-19 become mild, like a cold?Epidemiology and infection · 2024
    Review
  6. Review
  7. Article
  8. CROI 2024: Acute and Post-Acute COVID-19.Topics in antiviral medicine · 2024
    Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shang Yu GongCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.ORCID 0000-0001-8211-6207
Shilei DingCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Mehdi BenlarbiCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Yaozong ChenInfectious Disease Division, Department of Medicine of Uniformed Services, University of the Health Sciences, Bethesda, MD 20814-4712, USA.
Dani VézinaCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.ORCID 0000-0002-0780-8593
Lorie MarchittoCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Guillaume Beaudoin-BussièresCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Guillaume GoyetteCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.ORCID 0000-0003-3277-568X
Catherine BourassaCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.ORCID 0000-0003-1805-8860
Yuxia BoDepartment of Biochemistry, Microbiology and Immunology, Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Halima MedjahedCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Inès LevadeLaboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
Marzena PazgierInfectious Disease Division, Department of Medicine of Uniformed Services, University of the Health Sciences, Bethesda, MD 20814-4712, USA.ORCID 0000-0003-0594-5057
Marceline CôtéDepartment of Biochemistry, Microbiology and Immunology, Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.ORCID 0000-0002-4664-4325
Jonathan RichardCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Jérémie PrévostCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Andrés FinziCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.

Funding

CIHR FellowshipCIHR Operating grant
6 · The paper itself

Abstract

SARS-CoV-2 continues to infect millions of people worldwide. The subvariants arising from the variant-of-concern (VOC) Omicron include BA.1, BA.1.1, BA.2, BA.2.12.1, BA.4, and BA.5. All possess multiple mutations in their Spike glycoprotein, notably in its immunogenic receptor-binding domain (RBD), and present enhanced viral transmission. The highly mutated Spike glycoproteins from these subvariants present different degrees of resistance to recognition and cross-neutralisation by plasma from previously infected and/or vaccinated individuals. We have recently shown that the temperature affects the interaction between the Spike and its receptor, the angiotensin converting enzyme 2 (ACE2). The affinity of RBD for ACE2 is significantly increased at lower temperatures. However, whether this is also observed with the Spike of Omicron and sub-lineages is not known. Here we show that, similar to other variants, Spikes from Omicron sub-lineages bind better the ACE2 receptor at lower temperatures. Whether this translates into enhanced transmission during the fall and winter seasons remains to be determined.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19HumansMutationPeptidyl-Dipeptidase ASARS-CoV-2Spike Glycoprotein, CoronavirusTemperatureAngiotensin-Converting Enzyme 2Peptidyl-Dipeptidase ASpike Glycoprotein, CoronavirusACE2 affinityBA.4BA.5COVID-19OmicronRBDSARS-CoV-2Spike glycoproteintemperaturevariant of concern

Identifiers

PMID36298733
PMCPMC9607596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.